Am I a Candidate for GLP-1 Weight Loss in Las Vegas?
By Charles Kamen, MD, board-certified neurologist
Before you can compare GLP-1 medications, there is a more useful first question: are you even a candidate, and what should you ask your physician? This guide is for patients in Las Vegas and Henderson who want to know how a physician decides whether GLP-1 weight loss is appropriate, what candidacy actually depends on, and how to access a real evaluation locally — rather than ordering medication from a website. If you want the head-to-head breakdown of the two drugs themselves, see the full side-by-side comparison.
Tirzepatide vs semaglutide: how they differ
Semaglutide is a single-receptor GLP-1 agonist. Tirzepatide is a dual-receptor agonist that activates both GLP-1 and GIP receptors. The clinical implication is that tirzepatide, by engaging two pathways, can produce greater weight reduction on average in head-to-head trials.
Both medications are FDA-approved for chronic weight management in adults meeting specific clinical criteria. Both are dosed as weekly subcutaneous injections. Both are most effective when combined with lifestyle change — diet, training, sleep, and behavior. Neither is a stand-alone solution.
Who is a candidate for each?
The right choice depends on the patient, not the medication. A physician-led Las Vegas weight management evaluation considers BMI, prior weight loss attempts, medical history, current medications, lab work, and goals.
In general, tirzepatide may be considered for patients who have plateaued on semaglutide, patients with significant weight to lose, and patients who tolerate GLP-1 medications well. Semaglutide may be considered for first-line therapy, patients with milder weight loss goals, and patients with specific comorbidities like type 2 diabetes. The right answer is individual, not categorical.
How a Las Vegas physician chooses between them
At our Las Vegas peptide clinic, the choice between tirzepatide and semaglutide is made after a complete medical evaluation with Dr. Charles Kamen, MD. The $88 evaluation includes a clinical consultation, lab work, and a goal-based discussion.
We do not auto-prescribe the highest-dose version of either medication. We do not promise specific weight loss results. We do design protocols individually and supervise your care over time. If neither medication is appropriate, you get that answer directly.
Quick comparison: tirzepatide vs semaglutide
- Semaglutide: single GLP-1 receptor agonist; weekly injection; FDA-approved for weight management
- Tirzepatide: dual GLP-1/GIP agonist; weekly injection; FDA-approved for weight management
- Tirzepatide: greater average weight reduction in head-to-head trials
- Choice depends on patient — not medication preference or marketing
- Both require physician supervision, lab monitoring, and lifestyle support
Frequently asked questions
Which is better, tirzepatide or semaglutide?
There is no universal "better" — the right answer depends on your body, your history, your goals, and your response over time. A physician-led evaluation in Las Vegas can help you choose. See our <a href="/peptide-clinic-las-vegas">Las Vegas peptide clinic</a> page to schedule.
How much do tirzepatide and semaglutide cost in Las Vegas?
Protocol costs depend on the medication, dose, and your individualized plan. The initial medical evaluation is $88. See our <a href="/blog/peptide-therapy-cost-las-vegas">peptide therapy cost in Las Vegas guide</a> for the full breakdown.
Do you serve Henderson patients for weight management?
Yes — the majority of our patients come from Henderson, Green Valley, Anthem, and Seven Hills. See our <a href="/peptide-clinic-henderson">Henderson peptide clinic page</a>.
The tirzepatide vs semaglutide question is one of the most common weight management questions in Las Vegas right now. The right answer is not a marketing claim or a TikTok video — it is a complete medical evaluation. Schedule your $88 evaluation at our Las Vegas peptide clinic or our Henderson peptide clinic and Dr. Kamen will help you decide.
References
- Jastreboff AM, et al. NEJM. 2022;387(3):205-216. (SURMOUNT-1)
- Wilding JPH, et al. NEJM. 2021;384(11):989-1002. (STEP 1)
- Frías JP, et al. NEJM. 2021;385(6):503-515. (SURPASS-2)
Wondering what’s right for you?
Get a straight answer from board-certified neurologist Dr. Charles Kamen, MD. The evaluation is $88 and is applied toward your protocol if you continue care.